Hyper-CVAD方案序贯治疗复发难治性淋巴瘤的临床研究

Clinical Study of Hyper-CVAD Regimens Sequential Therapy for Relapsed or Refractory Lymphoma

目的探讨Hyper-CVAD方案序贯治疗复发难治性淋巴瘤的疗效和安全性。方法将24例复发难治性淋巴瘤患者,分为治疗组(Hyper-CVAD组)12例,对照组(自体造血干细胞移植组)12例,治疗组采用Hyper-CVAD方案序贯治疗3~4个周期以上,比较两组患者治疗效果。结果治疗组取得完全缓解6例,部分缓解4例,无效2例,完全缓解后复发2例;对照组取得完全缓解8例,死于并发症3例,部分缓解1例,完全缓解后复发4例,两组的无病生存率均为33.3%。结论 Hyper-CVAD方案治疗复发难治性淋巴瘤安全、有效,疗效与自体造血干细胞移植相当。

Objective To observe the efficacy and safety of hyper-CVAD regimens sequential therapy for relapsed or refractory lymphoma. Methods 24 patients with relapsed or refractory lymphoma were randomly divided into the treatment group( Hyper-CVAD group) and the control group( autologous hematopoietic stem cell transplantation group),each with 12 cases,the treatment group received hyper-CVAD regimens sequential therapy for 3 ~ 4 cycles,and clinical efficacy between the 2 groups were compared. Results Disease-free survival rates of the 2 group were 33. 3%. In the treatment group,6 patients achieved complete remission,partial remission 4 patients,2 cases were ineffective,2 cases relapsed after complete remission,The control group has 8 cases of complete remission,partial remission 1 case,4 cases relapsed after complete remission and 3 cases died of complications. Conclusion Hyper-CVAD regimen has equivalent efficacy with autologous hematopoietic stem cell transplantation regimen for patients with relapsed or refractory lymphoma.